New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy

被引：0
|
作者：
Chacon, Aurelia [1 ]
Bobin, Arthur [1 ]
Leleu, Xavier [1 ]
机构：
[1] CHU Poitiers, Serv Oncohematol, 2 Rue Mil,Cs 90577, F-86000 Poitiers, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 10期
关键词：
Multiple myeloma; CAR T; Anti-BCMA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：993 / 995
页数：3
相关论文
共 50 条
  • [1] Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
    Ri, Masaki
    Suzuki, Kenshi
    Ishida, Tadao
    Kuroda, Junya
    Tsukamoto, Taku
    Teshima, Takanori
    Goto, Hideki
    Jackson, Carolyn C.
    Sun, Huabin
    Pacaud, Lida
    Fujikawa, Ei
    Yeh, Tzu-Min
    Hatayama, Tomoyoshi
    Aida, Kensuke
    Sunagawa, Yoshihiro
    Iida, Shinsuke
    CANCER SCIENCE, 2022, 113 (12) : 4267 - 4276
  • [2] Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
    Merz, Maximilian
    Albici, Anca-Maria
    von Tresckow, Bastian
    Rathje, Kristin
    Fenk, Roland
    Holderried, Tobias
    Mueller, Fabian
    Tovar, Natalia
    Oliver-Caldes, Aina
    Vucinic, Vladan
    Kharboutli, Soraya
    Baermann, Ben-Niklas
    Ayuk, Francis
    Platzbecker, Uwe
    Stoelzel, Friedrich
    Schub, Nathalie
    Schmitz, Friederike
    Fandrei, David
    Born, Patrick
    Khandanpour, Cyrus
    Hanoun, Christine
    Hoerster, Keven
    Teichert, Marcel
    Jeker, Barbara
    Hoffmann, Michele
    Kroeger, Nicolaus
    de Larrea, Carlos Fernandez
    Pabst, Thomas
    Gagelmann, Nico
    HEMASPHERE, 2025, 9 (01):
  • [3] Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma
    Davis, James
    McGann, Mary
    Shockley, Abigail
    Hashmi, Hamza
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (06) : 473 - 475
  • [4] Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
    Hansen, Doris K.
    Dhakal, Binod
    Hamadani, Mehdi
    Dingli, David
    Jain, Tania
    Huff, Carol Ann
    Janakiram, Murali
    Liu, Yi-Hsuan
    De Braganca, Kevin C.
    Lodowski, Nicole
    Sander, Jennifer
    Okorozo, Peter
    Mcfarland, Lindsay
    Perciavalle, Matthew
    Huo, Stephen
    Qureshi, Zaina P.
    Patel, Krina K.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [5] Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
    Costa, Luciano J.
    Hari, Parameswaran
    Berdeja, Jesus G.
    De Stefano, Valerio
    Gay, Francesca
    Hooper, Becky
    Bartlett, Meaghan
    Haltner, Anja
    Rosta, Emily
    Kumar, Shaji
    Martin, Thomas
    Mateos, Maria-Victoria
    Moreau, Philippe
    Usmani, Saad Z.
    Olyslager, Yunsi
    Schecter, Jordan M.
    Roccia, Tito
    Garrett, Ashraf
    Lee, Sam
    Nesheiwat, Tonia
    Pacaud, Lida
    Zhou, Changwei
    Samjoo, Imtiaz A.
    Lin, Yi
    Diels, Joris
    Valluri, Satish
    Weisel, Katja
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (10) : 1759 - 1767
  • [6] Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
    Berdeja, Jesus G.
    Cohen, Adam D.
    Martin, Thomas
    Madduri, Deepu
    Pacaud, Lida
    Jagannath, Sundar
    FUTURE ONCOLOGY, 2023, 19 (18) : 1235 - 1247
  • [7] Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
    Chekol Abebe, Endeshaw
    Yibeltal Shiferaw, Mestet
    Tadele Admasu, Fitalew
    Asmamaw Dejenie, Tadesse
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
    Bar, Noffar
    Diels, Joris
    van Sanden, Suzy
    Mendes, Joao
    Hernando, Teresa
    Burnett, Heather
    Cost, Patricia
    Schecter, Jordan M.
    Lendvai, Nikoletta
    Patel, Nitin
    Ishida, Tadao
    Er, Jeremy
    Harrison, Simon J.
    Lopez-Munoz, Nieves
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (09) : 1597 - 1603
  • [9] CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
    Lin, Yi
    Martin, Thomas
    Usmani, Saad
    Berdeja, Jesus
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam
    Deol, Abhinav
    Htut, Myo
    Lesokhin, Alexander
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Jackson, Carolyn
    Yeh, Tzu-Min
    Banerjee, Arnob
    Zudaire, Enrique
    Madduri, Deepu
    delCorral, Christopher
    Pacaud, Lida
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S488 - S489
  • [10] Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
    Hansen, Doris K.
    Lu, Xiaoxiao
    Puglianini, Omar Castaneda
    Sorensen, Sonja
    Usmani, Saad Z.
    Zhang, Eileen
    Huo, Stephen
    Zhang, Yan
    Qureshi, Zaina P.
    Jagannath, Sundar
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345